MedCity News October 28, 2024
Novartis is getting global rights to a Monte Rosa Therapeutic molecular glue degrader drug in early clinical testing as a potential treatment for autoimmune disorders. The deal comes months after the pharma giant landed rights to an Arvinas targeted protein degrader for cancer.
The molecular glue degrader medicines furthest along in development are potential cancer treatments, but Monte Rosa Therapeutics is also researching how this therapeutic modality can treat immunological disorders. Novartis sees promise in a Monte Rosa drug candidate designed to degrade a protein associated with autoimmune disease and the pharmaceutical giant is paying $150 million for global rights to the program.
The sum is an upfront payment for the molecule, named MRT-6160. Boston-based Monte Rosa is still responsible...
Today's Sponsors
Today's Sponsor